Skip to main content
Clinical Trials/NCT01110811
NCT01110811
Completed
Not Applicable

A Randomized Controlled Trial Comparing Transoral Incisionless Fundoplication (TIF) Using EsophyX With Sham Procedure for the Treatment of PPI Dependent GERD: the TIF vs. Sham Study

EndoGastric Solutions4 sites in 3 countries60 target enrollmentApril 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gastroesophageal Reflux Disease
Sponsor
EndoGastric Solutions
Enrollment
60
Locations
4
Primary Endpoint
Proportion of patients in clinical remission
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The study objective is to evaluate the relative merits, safety and effectiveness of transoral incisionless fundoplication (TIF) in proton pump inhibitor (PPI) dependent GERD patients compared with sham procedure.

Detailed Description

Primary Effectiveness Endpoint: The proportion of patients in clinical remission after 6 months (without being classified as treatment failure). Secondary Effectiveness: PPI consumption, esophageal acid exposure, reduction in QOLRAD and GSRS scores and healing of reflux esophagitis.

Registry
clinicaltrials.gov
Start Date
April 2010
End Date
December 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18-80 years
  • On daily PPIs for \> 6 months
  • Documented PPI dependency
  • Persistent GERD symptoms without PPI therapy during the titration phase of the study
  • Evidence of two or more of the following while off PPI therapy (\> 10 days):
  • Erosive esophagitis (Los Angeles grade A-C)
  • Abnormal ambulatory pH study
  • Moderate to severe GERD symptoms
  • Normal or near normal esophageal motility (by manometry)
  • Patient willing to cooperate with post-operative dietary recommendations and assessment tests

Exclusion Criteria

  • BMI \> 35
  • Hiatal hernia \> 3 cm
  • Esophagitis LA grade D
  • Esophageal ulcer
  • Esophageal stricture
  • Barretts esophagus (Prague: C\>1, M\>2)
  • Esophageal motility disorder
  • Severe gastric paralysis
  • Pregnancy or plans for pregnancy in the next 12 months
  • Immunosuppression

Outcomes

Primary Outcomes

Proportion of patients in clinical remission

Time Frame: at 6 month follow-up

Fifty nine per cent of patients remained in clinical remission

Secondary Outcomes

  • Reduction in symptoms(at 6 moths follow-up)
  • Normalized esophageal acid exposure(at 6 months follow-up)
  • Healed reflux esophagitis(at 6 months follow-up)

Study Sites (4)

Loading locations...

Similar Trials